MDS Armamentarium Expands With Luspatercept Approval, Novel Compounds
Published: Monday, Apr 06, 2020
David P. Steensma, MD
The armamentarium in myelodysplastic syndromes (MDS) is slated to grow with agents such as luspatercept-aamt (Reblozyl), venetoclax (Venclexta), APR-246, and magrolimab, despite some of the challenges with drug development in the space, explained David P. Steensma, MD.
... to read the full story